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Indolent Lung Cancers—Time for a Paradigm Shift
A Review
Gunnar Hillerdal, MD, PhD
The present paradigm is that slow-growing and clinically unimpor-
tant lung cancers are very rare. Over the years, convincing evidence
for their existence in significant numbers has been dismissed, but
with computerized tomography scanning being increasingly common,
their reality can no longer be denied. The time is now ripe for a
paradigm shift—with consequences for screening as well as clinical
practice in the future. The doubling time of the tumor is probably the
most important factor for survival of the patient, and research on how
to measure this figure is urgent. Age, smoking habits, and comorbidities
of the patient are now the main factors when discussing treatment with
the patient; once we can predict the behavior of the cancer, i.e., whether
it is indolent or actually threatens the patient’s life, we will be able to
give better advice.
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The present paradigm is that most of untreated lung cancersare rapidly fatal, and consequently early surgery if pos-
sible is mandatory. A few reports have shown the existence of
a considerable number of slow-growing lung cancers.1–7
Nevertheless, such reports have often been dismissed.8,9 With
computerized tomography (CT) scanning, more evidence of
these indolent lung cancers is accumulating, and the time is
now ripe for a paradigm shift—with consequences for screen-
ing and clinical practice in the future. This article is a short
review of this evidence.
GROWTH RATE OF LUNG CANCER
Collins in 1956 suggested a now generally accepted
model of cancer growth,10 which was applied to lung cancer
in 1979.11 The cancer starts as a single cell, which grows
exponentially at a constant rate. A cell of 10 m will become a
tumor measuring 1 mm in diameter after 20 doublings; after 30,
it has reached a size of 1 cm; and after 40, 10 cm, where the
patient is estimated to die of his cancer burden11,12 (Table 1).
Lung cancers, especially adenocarcinomas, are mark-
edly heterogenous and their doubling times vary greatly
(Table 2).
The present tumor, node, metastasis classification di-
vides stage I (where there is no spread to any lymph nodes
nor anywhere else) into T1, with a diameter of less than 30
mm, and T2, with larger tumors. As seen in Table 1, the
“window” to detect a tumor of a size up to 30 mm is 5
doublings for a tumor discovered by a chest roentgenogram
and 3 more (i.e., 8 doublings) for a CT scan. For a rapidly
growing tumor with a doubling time of 30 days, there will be
150 “available days” to discover it with chest roentgenogram
and 240 days with CT scan—and from a 10 mm diameter tumor
to death (if not affected by some kind of treatment) there will be
only 300 days. For a slower-growing cancer, with a doubling
time of 500 days, the radiograph “window” will be 2500 days
(6.8 years), the CT one 4000 days (almost 11 years) and the
“survival time” from 10mm to death 5000 days (13.7 years). For
the extremely slow-growing ones, with a doubling time of 1500
days, multiply these figures with three.
For the above calculations, the growth rate is presumed
to be constant. Nevertheless, since a diameter of 1 cm
corresponds to 30 doublings, this cannot be true for tumors
with a doubling time of 2 years or more. By calculating
backwards and assuming a constant growth rate, in a 60-year-
old patient who has a lung cancer with a doubling time of 2
years, the cancer should then have started at birth, and for
those with longer doubling times even before that. Thus, we
must postulate that at least some tumors grow faster in the
beginning and some factor(s) (intrinsic in the cancer cells or
extrinsic from body defenses) will cause a slower growth
once the tumor reaches a certain size. Nevertheless, during
the time window that is of interest to us, a constant growth
rate seems to be the best fit to published data.
The slower the growth, the greater the chance to dis-
cover the cancer by chance or at screening. Nevertheless,
finding cancers with doubling times of 500 days or more and
removing them might not benefit the patient in terms of
survival, since death can occur from other diseases before the
cancer would have killed him or her. The possible gains from
surgery of a lung cancer in the individual patient will thus
depend on the doubling time of the tumor and the expected
survival of the patient.
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DISTRIBUTION OF FAST AND SLOW-GROWING
LUNG TUMORS
Survival of T1 Tumors
Many authors have found that survival of patients with
untreated (i.e., not surgically removed) T1 tumors is poor,
with only a minority surviving 5 years. Of 885 lung cancers
with a diameter of 6 to 15 mm, 33 (3.7%) were unresected;
their 8-year survival was 13%, compared with 71% for the
surgical cases.17 In another material of 19,699 stage I non-
small cell lung cancer, 16,184 underwent surgery with a
median overall survival of 69 months, whereas 1432 patients
(7%) did not receive any treatment and had a median overall
survival of only 9 months.18 Many similar studies exist.19,20
What is not immediately obvious from these studies is
that they are based on clinical material and therefore heavily
selected. The requirement for inclusion is a histologic diag-
nosis of lung cancer. An indolent lung cancer is likely to
present as a small nodule, in which a patient fit for surgery
will be aggressively investigated and then resected and in-
cluded in the material (with an excellent patient survival).
Nevertheless, if the patient is unfit for surgery, the nodule will
not be aggressively investigated and no histologic diagnosis
will be available (and if it is diagnosed, the patient is likely to
have a poor survival because of comorbidity making surgery
impossible). Thus, there tends to be a selection of surgical
cases in the early stages, and therefore no conclusions can be
drawn about the natural history of untreated stage I cancers.
Autopsy Findings
One way of determining the “true” occurrence of lung
cancers would be a thorough study of consecutive autopsy
materials. Unfortunately, this is no longer possible because
the autopsy rate has declined. Some older studies are avail-
able, showing a “reservoir” of undetected lung cancers, with
8 to 29% of all lung cancers being postmortem surprises.21–24
None of these studies specifically investigated for lung can-
cer, and it is highly likely that many small tumors are
undetected at routine autopsies.6
FINDINGS FROM SCREENINGS
Studies With Chest Roentgenogram
The results from studies on screening for lung cancer
performed in the days before CT can be conveniently sum-
marized as: more stage I lung cancers found, more lung
cancers resectable and with a good 5-year survival, but no
decrease in lung cancer specific mortality.25,26 Compatible
with this is the Atomic Bomb Survivors Study: biennial chest
radiographs were taken, and 107 histologically proven lung
cancers found. Resected adenocarcinomas had no better sur-
vival than those not resected.1
The Mayo Lung Project, which involved 9211 male
smokers between 1971 and 1983, showed no benefit in lung
cancer mortality from the screening at the end of the study.
An extended follow-up until 1996 has been done, and even
this median follow-up of more than 20 years failed to show
such a benefit. In the screened group, lung cancer mortality
was calculated to be 4.4 deaths per 1000 person-years, and in
the control group this figure was 3.9.5
CT Screening
Finding a tumor at size 5 mm instead of 10 mm will, as
seen above, mean that it is discovered three doublings earlier
(from 30 doublings we go down to 27). That this should mean
a large improvement (other than in lead time) seems doubt-
ful.27 In reality, the mean size of cancers discovered at CT
screening is above 1 cm (Table 1). No prospective random-
ized controlled CT studies have so far been published, but
many without controls. The general findings are: many times
the expected annual number of early lung cancers, a high
percentage of adenocarcinomas, and a high percentage of
resectable stage I tumors though all stages are seen.2,4,13,28–33
In the Early Lung Cancer Action Program (ELCAP)
and its international extension (I-ELCAP) baseline screening
was performed 1993 to 2006 on persons 40 to 85 years of age
and with a smoking history of up to 150 pack years. Depend-
ing on age and smoking history, the risk of lung cancer varied
from 0.07 to 6.8%.34 From baseline and repeated screening of
31,567 people, 484 have been diagnosed with lung cancer.
Eighty-five percent of those had clinical stage I disease, and
for these patients, the estimated 10-year survival was 88%.35
In one recently published study with 3 246 asymptom-
atic smokers or ex-smokers from two centers in the United
States and one in Italy were screened annually with CT scans.
TABLE 1. The Natural History of a Solid Lung Cancer
Which Grows Exponentially (from Geddes 1979 with some
additions)
Doublings
Number
of Cells Diameter Clinical Comments
0 1 10 m
20 106 1 mm Microscopic
27 108 5 mm Possible to see at CT
30 109 10 mm Detectable on chest radiograph
14 mm Mean size of cancers discovered at CT
screening
35 1010.5 30 mm Average size at diagnosis according to
Geddes; mean size of cancers
discovered at chest radiograph
screening
40 1012 100 mm Death
TABLE 2. Doubling Times for Lung Cancer (days); Mean
and (within brackets) Range
References Squamous Adenocarcinoma All
1 174 (39–441) 357 (27–741)
12 100 (30–210) 220 (60–330)
13 (30–1077)
14 215 (27–730)
4 129 533 452 (52–1733)
3 (42–1486)
15 Median 181; 22% 465
16 207
7 103 746 518 (10–5810)
Journal of Thoracic Oncology • Volume 3, Number 3, March 2008 Indolent Lung Cancers
Copyright © 2008 by the International Association for the Study of Lung Cancer 209
Follow-up was almost 4 years, and the “controls” were
theoretical ones from known smoking habits, age, etc. One
hundred forty-four lung cancers versus 44.5 expected (re-
sponse rate [RR]  3.2) and 109 surgical resections versus
10.9 expected (RR  10) were found. This, however, did not
translate into a better survival: there were 42 cases of ad-
vanced lung cancer in the screened group versus 33 expected,
and 38 lung cancer deaths occurred in the screened popula-
tion compared with 38.8 expected.33
ARE FASTER-GROWING LUNG CANCERS ALSO
MORE AGGRESSIVE THAN SLOW-GROWING
ONES?
Most studies find a statistically significant relation
between size and stage among T1 lung cancers, i.e., the
smaller the tumor, the more likely it is that it is pathologically
stage I.35,36 In the Surveillance, Epidemiology, and End Results
(SEER) registry data, pathologic stage I was found in 54% of
tumors with a diameter of 15 mm or less, 46% in those size 16
to 25 mm, and 34% in those 26 to 35 mm.36 From these results,
no conclusions can be drawn about whether fast-growing tumors
have a larger tendency to set metastases early than slow-growing
ones—which intuitively seems likely.26
Screen-detected small tumors can be divided into dif-
ferent groups according to findings in the microscope. Patho-
logically, destructive growth against alveolar structure leads
to a poorer survival with only 49% surviving 5 years, while
the figure for the others was 82.4%.37 Aggressive small
tumors (those with aneuploidity or a high S-phase fraction)
have the same survival as symptom-detected tumors, whereas
those without these findings have a significantly better sur-
vival.2 Poor differentiation is also a risk factor for recur-
rence.38 Thus, at screening, both aggressive and less aggres-
sive tumors are found.
EXPECTED SURVIVAL OF PATIENTS WITH
T1-TUMORS
Comorbidity
Most screening studies are directed at high-risk groups,
mainly smokers or ex-smokers. This guarantees a fairly high
yield of lung cancers, but also a high risk of comorbidity and
a lowered life expectancy, mainly because of other diseases
than lung cancer. Therefore, usually only asymptomatic in-
dividuals are included, minimizing this risk.
In an unselected cohort of smokers aged 60 years, only
50% will survive until they are 75-years-old.39,40 “Average”
cigarette smoking reduces the total life span by 6.8 years.40
Most of the deaths are because of an excess cardiovascular
disease. Chronic bronchitis causes a 50% increase in coro-
nary deaths; for every 10% decrease in FEV1, all-cause
mortality increases by 14%.41 Even if technically operable,
the majority of patients with lung cancer are or have been
smokers and have a lowered lung function.
As mentioned, in screening studies there is usually a
selection of more healthy persons, i.e., less comorbidity. In the
I-ELCAP study, the probability of surviving 10 years for a
60-year-old still smoking person with a smoking history of 30
pack years was 97%, and for one with 100 pack years 87%.
Amazingly, even an 80-year smoker with a 10 pack-year history
had an 86% chance to survive to 90 years, and for the 100
pack-year man who continued to smoke it was still 53%.34
HOW SOON CAN GROWTH BE DISCOVERED?
Because screening will yield a high incidence of non-
calcified small nodules (up to 50% in some materials), most
of which are judged to be benign, various recommendations
have been suggested for follow-up. The one in most frequent
use is suggested by the Fleischner Society which recom-
mends a new CT scan after time periods of 3 to 12 months,
depending on the size of the nodule and whether the patient
has a high or low risk of malignancy.42 It must also be taken
into account that there is a high degree of intra- and interob-
server disagreement on detection of individual pulmonary
nodules43 and that it is important to use the same technique at
the follow-up. With volumetric measurement growth in those
with fast-growing cancers larger than 5 mm can be seen after
30 days44 but usually longer time is necessary.3,45
Ground-glass opacity and air bronchogram indicate
slow growth (doubling time more than a year), whereas solid
tumors can grow faster.3,4 Another interesting possibility is
positron emission tomography scanning; there is a fair cor-
relation between metabolism (and hence the intensity of
uptake) and growth,14 and this should be further investigated.
Finally, biogenetics might in the future be the best way to
discriminate fast-growing tumors from slow-growing ones.
CONCLUSIONS
So far, the clinical approach to any patient with a small
confirmed or strongly suspected malignant single nodule has
been surgery unless the condition of the patient prohibits it,
based on the belief that practically all lung cancers will
rapidly cause the death of the patient if left untreated. As is
hopefully clear from this review, the growth rate of a nodule is
more important than its size—and a number of patients may not
benefit from surgery. Nevertheless, identifying these patients is
not currently possible and remains a challenge for the future.
Unlike as in prostate and mammary carcinoma, where
screening has shown that indolent cancers occur, we have in
the lungs unique possibilities to measure the growth of tumors.
Whenever serial CT scans and/or chest roentgenograms are
available, an effort to measure the doubling time of the tumor
should be made. If this is systematically done and related to
survival of the patient, pathologic findings, positron emission
tomography studies, and very possibly genetic studies of the
tumor, it might be possible to identify the indolent cancers, i.e.,
those which have a good prognosis even without surgery.
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